CARM
Price
$1.00
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
GLUE
Price
$5.92
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
50 days until earnings call
Ad is loading...

CARM vs GLUE

Header iconCARM vs GLUE Comparison
Open Charts CARM vs GLUEBanner chart's image
Carisma Therapeutics
Price$1.00
Change-$0.00 (-0.00%)
Volume$76.61K
CapitalizationN/A
Monte Rosa Therapeutics
Price$5.92
Change-$0.00 (-0.00%)
Volume$201.08K
CapitalizationN/A
View a ticker or compare two or three
CARM vs GLUE Comparison Chart
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CARM vs. GLUE commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a StrongSell and GLUE is a StrongSell.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (CARM: $1.00 vs. GLUE: $5.92)
Brand notoriety: CARM and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 36% vs. GLUE: 91%
Market capitalization -- CARM: $41.54M vs. GLUE: $363.33M
CARM [@Biotechnology] is valued at $41.54M. GLUE’s [@Biotechnology] market capitalization is $363.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $609.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 4 TA indicator(s) are bullish while GLUE’s TA Score has 6 bullish TA indicator(s).

  • CARM’s TA Score: 4 bullish, 6 bearish.
  • GLUE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than CARM.

Price Growth

CARM (@Biotechnology) experienced а +1.11% price change this week, while GLUE (@Biotechnology) price change was -6.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.17%. For the same industry, the average monthly price growth was +1.67%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

GLUE is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($363M) has a higher market cap than CARM($41.5M). GLUE YTD gains are higher at: 4.779 vs. CARM (-65.870). CARM has higher annual earnings (EBITDA): -72.61M vs. GLUE (-131.78M). GLUE has more cash in the bank: 262M vs. CARM (40.4M). CARM has less debt than GLUE: CARM (8.17M) vs GLUE (44.4M). CARM has higher revenues than GLUE: CARM (20.7M) vs GLUE (5.76M).
CARMGLUECARM / GLUE
Capitalization41.5M363M11%
EBITDA-72.61M-131.78M55%
Gain YTD-65.8704.779-1,378%
P/E RatioN/AN/A-
Revenue20.7M5.76M359%
Total Cash40.4M262M15%
Total Debt8.17M44.4M18%
FUNDAMENTALS RATINGS
CARM: Fundamental Ratings
CARM
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CARMGLUE
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 29 days ago
84%
Bullish Trend 9 days ago
88%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CRMAX12.110.04
+0.33%
CRM Small/Mid Cap Value Inv
IYMIX31.470.09
+0.29%
Delaware Ivy Mid Cap Growth I
JIGAX81.870.09
+0.11%
JPMorgan U.S. GARP Equity A
SBSDX44.390.01
+0.02%
Franklin S&P 500 Index D
TVEFX16.81N/A
N/A
Guggenheim RBP® Dividend P

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with PRME. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-0.99%
PRME - CARM
47%
Loosely correlated
+6.95%
ABCL - CARM
43%
Loosely correlated
+1.87%
NTLA - CARM
43%
Loosely correlated
+4.83%
ARDX - CARM
42%
Loosely correlated
-1.13%
GLUE - CARM
41%
Loosely correlated
+5.34%
More